Inogen (NASDAQ:INGN) Upgraded at StockNews.com

Inogen (NASDAQ:INGN) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

Separately, Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Friday.

Inogen Price Performance

Shares of NASDAQ:INGN traded down $0.58 on Tuesday, hitting $10.44. The company’s stock had a trading volume of 275,173 shares, compared to its average volume of 335,556. The company has a 50-day simple moving average of $9.90 and a 200 day simple moving average of $9.49. Inogen has a 1 year low of $4.68 and a 1 year high of $13.33. The company has a market capitalization of $247.64 million, a PE ratio of -4.64 and a beta of 1.04.

Institutional Trading of Inogen

Institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. purchased a new stake in Inogen during the second quarter valued at about $30,000. CWM LLC raised its stake in shares of Inogen by 2,185.9% during the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 6,339 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Inogen during the first quarter valued at about $81,000. Pitcairn Co. bought a new position in shares of Inogen during the first quarter valued at about $86,000. Finally, Oppenheimer Asset Management Inc. bought a new position in shares of Inogen during the first quarter valued at about $121,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.